Neuroone Medical Technologies (NMTC) Change in Accured Expenses (2013 - 2026)

Neuroone Medical Technologies (NMTC) has 14 years of Change in Accured Expenses data on file, last reported at $31133.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 4.35% year-over-year to $31133.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$211941.0 (down 3841.9% YoY) and the FY2025 annual result came in at -$54442.0, down 435.77% from the prior year.
• Change in Accured Expenses advanced to $31133.0 in Q1 2026, from -$619376.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.7 million in Q3 2022 to a low of -$1.4 million in Q1 2023.
• A 5-year average of -$5853.6 and a median of $73839.0 in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 1227.97% — and 2023, when it slumped 7447.94%.
• Tracing NMTC's Change in Accured Expenses over 5 years: stood at -$306125.0 in 2022, then tumbled by 69.4% to -$518584.0 in 2023, then rose by 10.66% to -$463292.0 in 2024, then slumped by 33.69% to -$619376.0 in 2025, then jumped by 105.03% to $31133.0 in 2026.
• The last three Change in Accured Expenses figures came in at $31133.0 (Q1 2026), -$619376.0 (Q4 2025), and $302463.0 (Q3 2025), per Business Quant data.